sprite-preloader
Anzeige
Mehr »
Mittwoch, 19.06.2019 Börsentäglich über 12.000 News von 609 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A2AG0F ISIN: SE0006091997 Ticker-Symbol: 1YR 
Aktie:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNOVIA AB Chart 1 Jahr
1-Woche-Intraday-Chart
IMMUNOVIA AB 1-Woche-Intraday-Chart
12.02.2019 | 15:10
(2 Leser)
Schrift ändern:
(0 Bewertungen)

PR Newswire·Mehr Nachrichten von PR Newswire

LUND, Sweden, Feb. 12, 2019 /PRNewswire/ --

Immunovia invites to a teleconference (in English) for investors, analysts and media on February 14, at 5:30 - 6:30 p.m. CET. Immunovia will publish the company's Full Year Report 2018 for the period January - December 2018 on Thursday, February 14, at 5:05 p.m. CET.

Mats Grahn, CEO will present Immunovia and comment on the Full Year Report 2018 followed by a Q&A-session. Please call in a few minutes in advance.

To attend, please dial-in at one of the numbers below:

SE: +46850558352
BE: +3226200547
CH: +41225675632
DE: +4969222220380
DK: +4578150109
FR: +33170750721
NL: +31207219495
NO: +4723500236
UK: +443333009035
US: +16467224956

For questions or interview bookings:
ir@immunovia.com

There will be an MP3-file available at Immunovia's webpage under Investors/audio-galley (https://immunovia.com/investors/audio-gallery/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/immunovia-ab/r/invitation-to-presentation-of-immunovia-s-full-year-report-2018-on-february-14--2019,c2739332

The following files are available for download:

https://mb.cision.com/Main/13121/2739332/989764.pdf

Immunovia, PR Telconference Q4


© 2019 PR Newswire